Laboratory Testing for von Willebrand Disease: Toward a Mechanism-Based Classification

Clinics in Laboratory Medicine

Volumn 29, Issue 2, 2009, Pages 193-228

  Torres, Richard ^a,b   Fedoriw, Yuri ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Classification; Laboratory testing; Mechanisms; Methods; von Willebrand disease; von Willebrand factor

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 8; COLLAGEN; DESMOPRESSIN; PROTHROMBIN; RISTOCETIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

BINDING ASSAY; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD GROUP TYPING; CRYOPRECIPITATE; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GEL ELECTROPHORESIS; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTHROMBIN TIME; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SPECTROSCOPY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON WILLEBRAND DISEASE; BIOLOGICAL MODEL; BLOOD; BLOOD GROUP ABO SYSTEM; CLASSIFICATION; DIAGNOSIS, MEASUREMENT AND ANALYSIS; ELECTROPHORESIS; METHODOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; PROTEIN TERTIARY STRUCTURE;

ABO BLOOD-GROUP SYSTEM; ELECTROPHORESIS; FLOW CYTOMETRY; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MODELS, BIOLOGICAL; PLATELET FUNCTION TESTS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 68149100727     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2009.06.005     Document Type: Review

References (79)

1. Zimmerman T.S., and Ruggeri Z.M. von Willebrand disease. Hum Pathol 18 2 (1987) 140-152
2. Schneider S.W., Nuschele S., Wixforth A., et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U S A 104 19 (2007) 7899-7903
3. Tsai H.-M. Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost 29 5 (2003) 479-488
4. Reininger A.J. VWF attributes-impact on thrombus formation. Thromb Res 122 Suppl 4 (2008) S9-13
5. Watson S.P., Auger J.M., McCarty O.J., et al. GPVI and integrin alphaIIb/beta3 signaling in platelets. Thromb Haemost 3 (2005) 1752-1762
6. Shattil S.J., and Newman P.J. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 104 (2004) 1606-1615
7. Wagner D.D. Cell biology of von Willebrand factor. Annu Rev Cell Biol 6 (1990) 217-246
8. de Wit T.R., and van Mourik J.A. Biosynthesis, processing and secretion of von Willebrand factor: biological implications. Baillieres Best Pract Res Clin Haematol 14 2 (2001) 241-255
9. Michaux G., Abbitt K.B., Collinson L.M., et al. The physiological function of von Willebrand's factor depends on its tubular storage in endothelial Weibel-Palade bodies. Dev Cell 10 2 (2006) 223-232
10. Ruggeri Z.M. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Baillieres Best Pract Res Clin Haematol 14 2 (2001) 257-279
11. Singh I., Shankaran H., Beauharnois M.E., et al. Solution structure of human von Willebrand factor studied using small angle neutron scattering. J Biol Chem 281 50 (2006) 38266-38275
12. Metcalf D.J., Nightingale T.D., Zenner H.L., et al. Formation and function of Weibel-Palade bodies. J Cell Sci 121 Pt 1 (2008) 19-27
13. Haberichter S.L., Shi Q., and Montgomery R.R. Regulated release of VWF and FVIII and the biologic implications. Pediatr Blood Cancer 46 5 (2006) 547-553
14. Borchiellini A., Fijnvandraat K., Wouter ten Cate J., et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of l-Deamino-8-DArginine vasopressin in humans. Blood 88 (1996) 2951-2958
15. Giblin J.P., Hewlett L.J., and Hannah M.J. Basal secretion of von Willebrand factor from human endothelial cells. [see comment]. Blood 112 4 (2008) 957-964
16. Blann A.D. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 95 1 (2006) 49-55
17. Mohlke K.L., and Ginsburg D. von Willebrand disease and quantitative variation in von Willebrand factor. [see comment]. J Lab Clin Med 130 3 (1997) 252-261
18. Denis C.V., Christophe O.D., Oortwijn B.D., et al. Clearance of von Willebrand factor. Thromb Haemost 99 2 (2008) 271-278
19. Kaufmann J.E., Oksche A., Wollheim C.B., et al. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 106 1 (2000) 107-116
20. Ruggeri Z.M., and Zimmerman T.S. von Willebrand factor and von Willebrand disease. [erratum appears in Blood 1988 Mar;71(3):830]. Blood 70 4 (1987) 895-904
21. Sadler J.E. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 71 4 (1994) 520-525
22. Sadler J.E., Budde U., Eikenboom J.C.J., et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. [see comment]. J Thromb Haemost 4 10 (2006) 2103-2114
23. Schlammadinger A., Vanhoorelbeke K., Laszlo P., et al. von Willebrand factor antigen latex immunoassays are affected to a different extent by rheumatoid factor. Clin Appl Thromb Hemost 12 2 (2006) 242-243
24. Hubbard A.R., and Heath A.B. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150). J Thromb Haemost 2 8 (2004) 1380-1384
25. Salem R.O., and Van Cott E.M. A new automated screening assay for the diagnosis of von Willebrand disease. Am J Clin Pathol 127 5 (2007) 730-735
26. De Vleeschauwer A., and Devreese K. Comparison of a new automated von Willebrand factor activity assay with an aggregation von Willebrand ristocetin cofactor activity assay for the diagnosis of von Willebrand disease. Blood Coagul Fibrinolysis 17 5 (2006) 353-358
27. Pinol M., Sales M., Costa M., et al. Evaluation of a new turbidimetric assay for von Willebrand factor activity useful in the general screening of von Willebrand disease. Haematologica 92 5 (2007) 712-713
28. Federici A.B., Canciani M.T., Forza I., et al. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels. Haematologica 89 1 (2004) 77-85
29. Budde U., Pieconka A., Will K., et al. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost 32 5 (2006) 514-521
30. Smejkal G.B., Shainoff J.R., and Kottke-Marchant K.M. Rapid high-resolution electrophoresis of multimeric von Willebrand Factor using a thermopiloted gel apparatus. [erratum appears in Electrophoresis 2003 May;24(9):1482]. Electrophoresis 24 4 (2003) 582-587
31. Favaloro E.J. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 33 8 (2007) 727-744
32. Favaloro E.J. A better approach to monitoring of therapy in von Willebrand disease?. [comment]. Thromb Haemost 100 3 (2008) 371-373
33. Hayward C.P.M., Harrison P., Cattaneo M., et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. [see comment]. J Thromb Haemost 4 2 (2006) 312-319
34. Favaloro E.J. Clinical utility of the PFA-100. Semin Thromb Hemost 34 8 (2008) 709-733
35. van Vliet H.H.D.M., Kappers-Klunne M.C., Leebeek F.W.G., et al. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. [see comment]. Thromb Haemost 100 3 (2008) 462-468
36. Favaloro E.J., Patterson D., Denholm A., et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. [comment]. Br J Haematol 139 4 (2007) 623-626
37. Miller J.L., Kupinski J.M., Castella A., et al. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease. J Clin Invest 72 5 (1983) 1532-1542
38. Sztukowska M., Gallinaro L., Cattini M.G., et al. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Br J Haematol 143 1 (2008) 107-114
39. Haberichter S.L., Balistreri M., Christopherson P., et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 108 10 (2006) 3344-3351
40. Haberichter S.L., Castaman G., Budde U., et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 111 10 (2008) 4979-4985
41. Chen D., Daigh C.A., Hendricksen J.I., et al. A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF: RCo) activity assay by flow cytometry. J Thromb Haemost 6 2 (2008) 323-330
42. Giannini S., Mezzasoma A.M., Leone M., et al. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. Haematologica 92 12 (2007) 1647-1654
43. Kempfer A.C., Silaf M.R., Farias C.E., et al. Binding of von Willebrand factor to collagen by flow cytometry. Am J Clin Pathol 111 3 (1999) 418-423
44. Torres R, Levene M. Clinical multimer analysis of vWF by fluctuation spectroscopy, In: SPIE Photonics West; 24-29 January 2009; San Jose, CA, Photonics West 2009-BiOS: Biomedical Optics (Special Collection) Proceedings of SPIE Volume: CDS329, SPIE, Bellingham, WA, 2009. Abstract# 7186-15.
45. Gill J.C., Endres-Brooks J., Bauer P.J., et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69 6 (1987) 1691-1695
46. Souto J.C., Almasy L., Muniz-Diaz E., et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 20 8 (2000) 2024-2028
47. Schleef M., Strobel E., Dick A., et al. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 128 1 (2005) 100-107
48. Davies J.A., Collins P.W., Hathaway L.S., et al. Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group. Blood 109 7 (2007) 2840-2846
49. Miller C.H., Haff E., Platt S.J., et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 1 10 (2003) 2191-2197
50. Gallinaro L., Cattini M.G., Sztukowska M., et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 111 7 (2008) 3540-3545
51. Jenkins P.V., and O'Donnell J.S. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?. Transfusion 46 10 (2006) 1836-1844
52. Popov J., Zhukov O., Ruden S., et al. Performance and clinical utility of a commercial von Willebrand factor collagen binding assay for laboratory diagnosis of von Willebrand disease. Clin Chem 52 10 (2006) 1965-1967
53. Casonato A., Pontara E., Bertomoro A., et al. Fainting induces an acute increase in the concentration of plasma factor VIII and von Willebrand factor. Haematologica 88 6 (2003) 688-693
54. Tosetto A., Rodeghiero F., Castaman G., et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 4 4 (2006) 766-773
55. Bowman M., Mundell G., Grabell J., et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. Thromb Haemost 6 (2008) 2062-2066
56. Gupta P.K., Saxena R., Adamtziki E., et al. Genetic defects in von Willebrand disease type 3 in Indian and Greek patients. Blood Cells Mol Dis 41 2 (2008) 219-222
57. Tamura A, Iwata M, Fukunishi S, et al. Identification of newly polymorphic intron 40 markers of the von Willebrand factor gene in a Japanese population. Legal Medicine, in press. doi:10.1016/j.legalmed.2008.11.004.
58. Goodeve A., Eikenboom J., Castaman G., et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). [erratum appears in Blood 2008 Mar 15;111(6):3299-300]. Blood 109 1 (2007) 112-121
59. James P.D., Notley C., Hegadorn C., et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 109 1 (2007) 145-154
60. Budde U., Schneppenheim R., Eikenboom J., et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). [see comment]. J Thromb Haemost 6 5 (2008) 762-771
61. Tjernberg P., Vos H.L., Castaman G., et al. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost 2 2 (2004) 257-265
62. Michiels J.J., Berneman Z., Gadisseur A., et al. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease. Clin Appl Thromb Hemost 12 4 (2006) 397-420
63. Victor M., Rugeri L., Nougier C., et al. Contribution of genetical analysis for diagnosis of von Willebrand's disease type 2B. Haemophilia 15 (2009) 610-612
64. Federici A, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood (online prepublication Sep 19, 2008). doi:10.1182/blood-2008-04-152280.
65. Nurden P., Debili N., Vainchenker W., et al. Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. Blood 108 8 (2006) 2587-2595
66. Casonato A., De Marco L., Gallinaro L., et al. Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys2362Phe mutation in the B2 domain. Thromb Haemost 97 4 (2007) 527-533
67. Baronciani L., Cozzi G., Canciani M.T., et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 30 3 (2003) 264-270
68. Laje P., Shang D., Cao W., et al. Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy. Blood 113 10 (2009) 2172-2180
69. Franchini M., Montagnana M., and Lippi G. Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease. Int J Lab Hematol 30 2 (2008) 91-94
70. Franchini M., and Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol 82 5 (2007) 368-375
71. Koo B.-H., Oh D., Chung S.Y., et al. Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients. Thromb Res 105 6 (2002) 471-476
72. Galbusera M., Noris M., Rossi C., et al. Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. The Italian Registry of Familial and Recurrent HUS/TTP. Blood 94 2 (1999) 610-620
73. Casonato A., Fabris F., Pontara E., et al. Diagnosis and follow-up of thrombotic thrombocytopenic purpura by means of von Willebrand factor collagen binding assay. Clin Appl Thromb Hemost 12 3 (2006) 296-304
74. Martinelli I. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 42 1 (2005) 49-55
75. Franchini M., and Lippi G. Von Willebrand factor and thrombosis. Ann Hematol 85 7 (2006) 415-423
76. Bongers T.N., de Maat M.P.M., van Goor M.-L.P.J., et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 37 11 (2006) 2672-2677
77. Folsom A.R., Rosamond W.D., Shahar E., et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 100 7 (1999) 736-742
78. Tsai A.W., Cushman M., Rosamond W.D., et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). [see comment]. Am J Med 113 8 (2002) 636-642
79. Nichols W.L., Hultin M.B., James A.H., et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). [see comment]. Haemophilia 14 2 (2008) 171-232